{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T06:34:49Z","timestamp":1773815689266,"version":"3.50.1"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003009","name":"Science and Technology Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005622","name":"Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005622","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"\n Purpose<\/jats:title>\n To comprehensively and systematically explore adverse drug reactions (ADRs) associated with ophthalmic atropine, providing evidence-based safety references for clinical medication practices.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Signal detection for ophthalmic atropine-associated ADRs was conducted using the Information Component (IC) and Reporting Odds Ratio (ROR) methods, analyzing data from the inception of the FDA Adverse Event Reporting System (FAERS) database through the second quarter of 2025.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n The FAERS database contained 425 reports of ophthalmic atropine-associated ADRs, with 83 positive signals detected. These signals primarily involved eye disorders, nervous system disorders, injury, poisoning and procedural complications, and infections and infestations. Endophthalmitis (\n n<\/jats:italic>\n \u202f=\u202f74, IC\n 025<\/jats:sub>\n \u202f=\u202f6.62, ROR\n 025<\/jats:sub>\n \u202f=\u202f101.90) was the most frequent and strongest ADR signal detected. Other high-intensity ADR signals were choroiditis (IC\n 025<\/jats:sub>\n \u202f=\u202f6.05, ROR\n 025<\/jats:sub>\n \u202f=\u202f69.26), intraocular pressure increased (IC\n 025<\/jats:sub>\n \u202f=\u202f5.77, ROR\n 025<\/jats:sub>\n \u202f=\u202f56.93), visual acuity reduced (IC\n 025<\/jats:sub>\n \u202f=\u202f5.46, ROR\n 025<\/jats:sub>\n \u202f=\u202f45.74), mydriasis (IC\n 025<\/jats:sub>\n \u202f=\u202f5.36, ROR\n 025<\/jats:sub>\n \u202f=\u202f43.34), and uveitis (IC\n 025<\/jats:sub>\n \u202f=\u202f5.36, ROR\n 025<\/jats:sub>\n \u202f=\u202f42.93). Additionally, eye pain (\n n<\/jats:italic>\n \u202f=\u202f64, IC\n 025<\/jats:sub>\n \u202f=\u202f4.99, ROR\n 025<\/jats:sub>\n \u202f=\u202f32.90) represented another frequently reported ADR after endophthalmitis. Of the preferred terms, 81.93% were assigned a grade of weak clinical priority, with the remainder (18.07%) falling into the moderate category.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n Ophthalmic atropine demonstrates potential ADR burdens in ocular systems, necessitating heightened clinical vigilance and prompt risk mitigation strategies to ensure medication safety. It should be noted that these findings represent safety signals from a spontaneous reporting database, not incidence estimates or proof of causality.<\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fmed.2026.1798521","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:38:48Z","timestamp":1773812328000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A systemic pharmacovigilance assessment of ophthalmic atropine: signal detection and clinical prioritization from the FAERS database"],"prefix":"10.3389","volume":"13","author":[{"given":"Zihang","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jizhou","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, Faculty of Health Service, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenting","family":"Cai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunhong","family":"Luo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Liang","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruoyi","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chengyu","family":"Hu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tu","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Tenth People\u2019s Hospital, School of Medicine, Tongji University","place":["Shanghai, China"]},{"name":"Department of Ophthalmology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia","family":"He","sequence":"additional","affiliation":[{"name":"Department of Health Statistics, Faculty of Health Service, Naval Medical University","place":["Shanghai, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center","place":["Shanghai, China"]},{"name":"Department of Ophthalmology, The Third People\u2019s Hospital of Bengbu","place":["Bengbu, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1080\/17425247.2021.1909568","article-title":"Atropine in topical formulations for the management of anterior and posterior segment ocular diseases","volume":"18","author":"Garc\u00eda Del Valle","year":"2021","journal-title":"Expert Opin Drug Deliv"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"101410","DOI":"10.1016\/j.preteyeres.2025.101410","article-title":"Interventions to reduce incidence and progression of myopia in children and adults","volume":"109","author":"Yam","year":"2025","journal-title":"Prog Retin Eye Res"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine Eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1001\/jamaophthalmol.2017.1091","article-title":"Efficacy and adverse effects of atropine in childhood myopia: a Meta-analysis","volume":"135","author":"Gong","year":"2017","journal-title":"JAMA Ophthalmol."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1002\/jcph.2320","article-title":"Incidence of adverse events induced by atropine in myopic children: a Meta-analysis","volume":"63","author":"Sun","year":"2023","journal-title":"J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.4103\/ijo.IJO_165_18","article-title":"Allergic reactions to atropine eye drops for retardation of progressive myopia in children","volume":"66","author":"Kothari","year":"2018","journal-title":"Indian J Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1001\/jamaophthalmol.2025.3090","article-title":"Ocular risks of topical atropine prescriptions among Taiwanese children","volume":"143","author":"Liu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1001\/jama.2022.24162","article-title":"Effect of low-concentration atropine Eyedrops vs placebo on myopia incidence in children: the LAMP2 randomized clinical trial","volume":"329","author":"Yam","year":"2023","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1001\/jamaophthalmol.2025.2321","article-title":"Orthokeratology, 0.04% atropine, and 0.01% atropine for myopia control: a randomized clinical trial","volume":"143","author":"Xu","year":"2025","journal-title":"JAMA Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s40264-014-0146-y","article-title":"Performance of probabilistic method to detect duplicate individual case safety reports","volume":"37","author":"Tregunno","year":"2014","journal-title":"Drug Saf"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"616505","DOI":"10.3389\/fphar.2021.616505","article-title":"Cardiotoxicity induced by immune checkpoint inhibitors: a pharmacovigilance study from 2014 to 2019 based on FAERS","volume":"12","author":"Chen","year":"2021","journal-title":"Front Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","article-title":"Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery","volume":"22","author":"Nor\u00e9n","year":"2013","journal-title":"Stat Methods Med Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1186\/s40425-019-0754-2","article-title":"Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system","volume":"7","author":"Zhai","year":"2019","journal-title":"J Immunother Cancer"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1177\/2047487320915663","article-title":"Adverse events with sacubitril\/valsartan in the real world: emerging signals to target preventive strategies from the FDA adverse event reporting system","volume":"28","author":"Gatti","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"996179","DOI":"10.3389\/fpubh.2022.996179","article-title":"Gastrointestinal adverse events associated with semaglutide: a pharmacovigilance study based on FDA adverse event reporting system","volume":"10","author":"Shu","year":"2022","journal-title":"Front Public Health"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/eye.2012.279","article-title":"Prescription of atropine eye drops among children diagnosed with myopia in Taiwan from 2000 to 2007: a nationwide study","volume":"27","author":"Fang","year":"2013","journal-title":"Eye (Lond)"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3390\/ph17030321","article-title":"New approaches to overcoming antimicrobial resistance in endophthalmitis","volume":"17","author":"Garcia O'Farrill","year":"2024","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1167\/iovs.18-23783","article-title":"Epidemiology and mortality-related prognostic factors in Endophthalmitis","volume":"59","author":"Weng","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1128\/CMR.00113-16","article-title":"Bacterial and fungal endophthalmitis","volume":"30","author":"Durand","year":"2017","journal-title":"Clin Microbiol Rev"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"xx","DOI":"10.1016\/j.ajo.2017.11.021","article-title":"Endophthalmitis: then and now","volume":"187","author":"Relhan","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1089\/jop.2006.22.41","article-title":"Prevention of myopia progression with 0.05% atropine solution","volume":"22","author":"Lee","year":"2006","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/j.ophtha.2024.03.013","article-title":"Five-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 4 report","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"E161","DOI":"10.1097\/OPX.0b013e31823ac4c1","article-title":"Does atropine use increase intraocular pressure in myopic children?","volume":"89","author":"Wu","year":"2012","journal-title":"Optom Vis Sci"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/ICU.0b013e32808738d5","article-title":"Drug-induced acute angle closure glaucoma","volume":"18","author":"Lachkar","year":"2007","journal-title":"Curr Opin Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s12886-016-0297-y","article-title":"Effects of topical atropine on intraocular pressure and myopia progression: a prospective comparative study","volume":"16","author":"Lee","year":"2016","journal-title":"BMC Ophthalmol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.18240\/ijo.2019.08.16","article-title":"Atropine 0.01% eye drops slow myopia progression: a systematic review and meta-analysis","volume":"12","author":"Zhao","year":"2019","journal-title":"Int J Ophthalmol"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"179","DOI":"10.4103\/tjo.TJO-D-24-00026","article-title":"Impact of atropine use for myopia control on intraocular pressure in children: a comprehensive review including postpupil dilation intraocular pressure changes","volume":"14","author":"Chen","year":"2024","journal-title":"Taiwan J Ophthalmol"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1159\/000538332","article-title":"Increase of intraocular pressure after application of 0.125% atropine eye drops in children using Ortho-K contact lenses","volume":"15","author":"Lee","year":"2024","journal-title":"Case Rep Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","article-title":"Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05, 0.025, and 0.01% atropine eye drops in myopia control","volume":"126","author":"Yam","year":"2019","journal-title":"Ophthalmology"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","article-title":"Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study: phase 2 report","volume":"127","author":"Yam","year":"2020","journal-title":"Ophthalmology"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"bjophthalmol-2019-315440","DOI":"10.1136\/bjophthalmol-2019-315440","article-title":"Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression","volume":"104","author":"Fu","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1007\/s10792-020-01356-x","article-title":"Part-time use of 1% atropine eye drops for prevention of myopia progression in children","volume":"40","author":"Foo","year":"2020","journal-title":"Int Ophthalmol"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","article-title":"Atropine 0.01% Eyedrops significantly reduce the progression of childhood myopia","volume":"31","author":"Clark","year":"2015","journal-title":"J Ocul Pharmacol Ther"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/eye.2016.78","article-title":"Effectiveness study of atropine for progressive myopia in Europeans","volume":"30","author":"Polling","year":"2016","journal-title":"Eye (Lond)"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ophtha.2011.07.031","article-title":"Atropine for the treatment of childhood myopia: safety and efficacy of 0.5, 0.1, and 0.01% doses (atropine for the treatment of myopia 2)","volume":"119","author":"Chia","year":"2012","journal-title":"Ophthalmology"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","article-title":"Maximum atropine dose without clinical signs or symptoms","volume":"90","author":"Cooper","year":"2013","journal-title":"Optom Vis Sci"},{"key":"ref37","year":"2026"},{"key":"ref38","year":"2025"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.exer.2013.02.007","article-title":"An updated view on the role of dopamine in myopia","volume":"114","author":"Feldkaemper","year":"2013","journal-title":"Exp Eye Res"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.arcped.2013.01.012","article-title":"Effets syst\u00e9miques des collyres mydriatiques atropiniques chez deux enfants [systemic adverse effects of topical ocular instillation of atropine in two children]","volume":"20","author":"Princelle","year":"2013","journal-title":"Arch Pediatr"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1097\/OPX.0000000000000097","article-title":"Treatment outcomes of myopic anisometropia with 1% atropine: a pilot study","volume":"90","author":"Lin","year":"2013","journal-title":"Optom Vis Sci"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.addr.2006.07.027","article-title":"Challenges and obstacles of ocular pharmacokinetics and drug delivery","volume":"58","author":"Urtti","year":"2006","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798521\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T05:38:49Z","timestamp":1773812329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1798521\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":42,"alternative-id":["10.3389\/fmed.2026.1798521"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1798521","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"article-number":"1798521"}}